Background. Thromboembolic events may be related to thrombotic deposition on prosthetic valves. In a left ventricular assist device (LVAD) that contains two porcine pericardial bioprosthetic valves in addition to significant associated biomaterial placement, this may be particularly true. Thrombotic deposits on valves removed from LVADs at autopsy or heart transplantation were scored to determine (1) the nature and location of valvular deposition, (2) whether deposition was related to thromboembolic events, (3) correlations between deposition and patient hemodynamic and coagulation parameters, and (4) implant time dependency.
T he placement of prosthetic or bioprosthetic valves in humans is associated with a finite risk of thromboembolism. '-3 In several left ventricular assist device (LVAD) designs, two valves are located between the pumping sac and the inflow and outflow conduits, respectively. Since the biomaterial surfaces of the conduits and pumping sac may impart a thromboembolic risk or platelet activation potential of their own4, 5 and since LVAD patients have been shown to have elevated indices of coagulation and platelet activation,6,7 it seems reasonable to expect that the valves in these patients would be subject to increased deposition and embolization. Thromboembolism has indeed been a major complication faced over the course of LVAD implantation,6,8 and the valves associated with these devices are considered likely sources for the generation of emboli. Reducing the incidence of such thromboembolism in LVAD patients has been the motivation for many alterations in device design and anticoagulation protocols. At included arterial pressure, heart rate, pump rate, pump fill volume, pump residual volume, pump volumetric output, and the cardiac index.
Valve Retrieval and Scoring
At the time of heart transplantation or autopsy, the LVAD was explanted in an assembled state from the body. Saline was gently passed through the device to remove excess blood, and the conduits were then unscrewed from the pumping sac to allow valve retrieval. The conduits and pumping sac were generally found to be free of deposition. The inflow and outflow valves were photographed individually against a uniform cloth background for convex (upstream) valve the percent of the strut length containing deposition for each of the three struts was averaged. For the two patients implanted with secondary valves, the scores for the secondary valves were used for the characterization of the location and nature of valve deposition as well as how deposition varied as a function of time implanted. The secondary valve scores were not used for the other correlations.
Statistical Methods
An intraclass correlation coefficient for a fixed set of raters was calculated to assess rater reliability for the parameters scored on each valve side, as was the P value indicating whether the correlation coefficient was significantly different from zero. ' 
Results

Scores by Valve and Valve Side
The data are presented to compare the four valve sides of the LVAD in Fig 3. The results given in this figure demonstrate that the concave side of the inflow valve experiences the heaviest thrombus deposition in terms of thrombus area as well as deposition that is the darkest red. The convex side of the inflow valve has the highest percentage of cusp area involved with thrombus. The average percent of the inflow valve strut length involved with thrombus (37±36%) was not significantly different from the outflow valve (46±28%). Examples of light and heavy deposition in terms of thrombus area are seen in Fig 4 for outflow valve and lower on the concave valve side (P<.01). The outflow valve had a greater average percent strut length involved with thrombus than the inflow valve, but this was not found to be significant (P>.05).
As a test of the scoring system, the thrombus area on the concave side of the inflow valve was plotted against the average percent of the inflow strut length involved with thrombus. One would anticipate that these variables might be related: an increased involvement on the strut would be seen from the direct photograph of the concave side of the valve and enter into the thrombus area determination, along with any thrombus an involved strut might be connected to on the valve support ring. Fig 5 shows that such a relation does exist between these variables and serves as a qualitative check of the scoring system.
The intraclass correlation for the parameters scored was found to be highly significant in all cases (P<.001), indicating good agreement between individual scorers. Correlation estimates were >0.8 for the majority of parameters and valve sides scored. A notable exception occurred with scores for the outflow valve convex side, which generally had lower deposition and smaller correlation estimates (range, 0.3 to 0.6).
To look for temporal trends in valve deposition, the dependence of the thrombus area score on the duration of device implant is seen in Fig 6 for With the present increase in the waiting period for heart transplantation and plans for chronic support of transplant-ineligible populations, the need to control LVAD-associated thrombogenesis in devices experiencing this problem will become increasingly critical. Determining the mechanisms of thromboembolism in LVAD recipients will provide a foundation for attempts at controlling this process.
It was observed at device explantation that the bioprosthetic valves of the Novacor LVAD have thrombotic deposition to various degrees but generally in excess of that associated with valve placement alone in the cardiac position.'4 (Implantation periods for valves in the cardiac position, however, are on average much longer than for the LVAD.) The general notion has been that heavy valvular deposition would be associated with an increased risk for thromboembolism in that patient, although no analysis has been performed to confirm or reject this hypothesis. This study set out to quantify the deposition phenomenon, determine whether there were any apparent temporal trends in deposition, relate deposition to thromboembolic risk, and correlate deposition parameters with coagulation and hemodynamic patient parameters measured over the course of implantation.
Results from this study indicate that deposition occurs predominantly on the inflow versus the outflow valve and on the concave (downstream) versus the convex (upstream) valve side. Of the four valve sides, the inflow concave side, which rests within the device's pumping sac, had the heaviest deposition. Regions of recirculation, leading to low convection of platelet agonists from the region, coupled with increased platelet/ platelet and platelet/surface contact, may exist and contribute to this heavy deposition. Additionally, thrombotic deposition in a low shear region such as this might be expected to be rich in fibrin and red cells (similar to venous thrombosis). Scoring of the "redness" of deposition supports this concept: this area was the darkest red in color. In contrast to this deposition, the convex side of the inflow valve had the "whitest" or most arterial-like deposition. This is congruent with arterial-like, platelet-rich deposition in a high-shear region.
One weakness of the scoring system used was the lack of a reference point on the removed valve to indicate how it was oriented within the pumping sac. Had this information existed in our retrospective study, a more spatially precise quantification method, such as that applied by Pantalos et al15 to LVAD-associated valves in calves, might have been used. Information thus obtained might provide more specific information regarding the relation of the average shear experienced by a region and thrombotic deposition.
It was thought before evaluation of the data that there might be a temporal relation in valvular deposition. Several authors observed sharp increases in thrombotic and coagulation parameters in the first week of LVAD or total artificial heart implantation, followed by a return to normal or near-normal levels.6,7 Also, Pifarre et al'6 noted an increase in thrombolytic parameters in the course of total artificial heart implantation. The possibility of a fluctuating deposition dependent on the thrombotic/thrombolytic balance was considered. In this scenario, a peak in deposition would be expected at some point during the implantation followed by thrombolytic degradation to a lower, more stable level. The data in Fig 6 may support this model. A peak does appear to occur, but the data are insufficient to warrant any firm conclusions. It was also noted that the average time until a patient's first thromboembolic episode was 38±37 days, which is approximately the time at which a peak occurs in the data. Here again, a relation is entirely speculative because of the scatter in the data.
The valves that were removed from two neurological event patients (at postoperative days 69 and 245) had below-average thrombotic deposition on the concave side of the inflow valve. This may have been a result of the extended time these valves were implanted. Given that substantial thrombotic deposition could occur within 2 days of implantation and given the risks associated with valve replacement, this procedure is not considered worthwhile at this time.
Of prime interest was the difference in thrombotic deposition on the concave side of the inflow valve for thromboembolic event and nonevent patient groups. This result seems to indicate that the relatively heavy deposition seen on this valve might either be the source for thromboemboli or serve as an indicator of hyperaggregable platelets that deposit on this surface as well as forming emboli in the fluid phase. Deposition on the struts of the outflow valve was also significantly higher in the thromboembolic event patient group. These struts are the last valve surface seen by the blood before it exits from the device toward the vasculature. Thromboemboli departing from this surface may not be subject to aggregate breakup or readhesion, as those emboli generated farther upstream in the device would be.
The rate of thromboembolic complications seen in this patient group is comparable to that seen for other ventricular assist devices.'7-'9 Recently, a substantially lower incidence of thromboembolic complications has been reported with one particular device.20 In terms of overall success in bridging patients to heart transplantation, however, the Novacor LVAD bridged 78% of the patients in this study successfully to heart transplantation and hospital discharge.
Correlation of thrombotic deposition for each patient with coagulation and hemodynamic parameters measured and averaged over the course of implantation identified potentially important relations. An earlier study by the authors examined the relation between hematologic parameters and thromboembolic events in this same patient group.6 The platelet secretion product PF4 was found to be significantly higher in thromboembolic event patients compared with nonevent patients. In the present study, PF4 was found to be positively correlated with the percent of cusp thrombotic coverage on the inflow valve. This is the first valvular surface seen by platelets entering the device. Preactivated platelets in the circulation might be more likely to deposit when they impinge on this surface. Activation of these platelets may occur proximally on the Dacron conduit leading to this valve. Dacron graft implantation alone is associated with chronically high levels of PF4 and f3-thromboglobulin. 4 Additionally, the authors have demonstrated a high thrombin activity on this conduit surface at device explant.13 (Thrombin is a potent activator of platelets.)
Hemodynamics were also implicated in valvular deposition. The volumetric pump output was negatively correlated with thrombotic deposition on the concave side of the inflow valve (Fig 7) . Lower flow through the pump might lead to reduced convection and longer residence times within the pumping sac. Contact time and platelet agonist concentrations would be increased in this case. The correlation found supports this model. Further, data from the patient population demonstrate that pump output in thromboembolic event patients was lower than for their nonevent counterparts. LVAD hemodynamics are thus related to valvular deposition, which is also related to thromboembolic events. This result is encouraging, since hemodynamics may be relatively easy to control as opposed to the biochemical reactions on the biomaterial surfaces. In support of this concept, recent in vitro flow visualization studies in the present Novacor LVAD demonstrated the effect of modifying pumping parameters on fluid velocity fields in the valvular region.2' Animal experimentation with an earlier version of this device also qualitatively showed the importance of local flow in valve thrombotic deposition.22 Increased control and awareness of the role of pumping parameters and device design from a flow profile perspective may lead to reduced thromboembolic risk in LVAD patients.
Summary
It has been shown that use of a retrospective scoring procedure for a number of characteristics of the porcine trileaflet valves associated with the Novacor LVAD can yield meaningful insights into the thrombogenic process associated with LVADs, despite a relatively limited patient population. The location of heaviest thrombotic deposition was isolated within the device as the concave side of the inflow valve. Scoring results of the deposition color suggest that this deposition may be characteristic of that found in low-shear environments. Patients who experienced thromboembolic events were shown to have larger deposits on this valve side. Platelet activation was also related to deposition seen on a valve surface (inflow, convex side) experiencing high shear. Finally, hemodynamics, or more precisely the LVAD volumetric pump output, was found to be correlated with valvular deposition, confirming the notion that "good washing" within the pumping sac reduces thrombotic deposition.
